Cotadutide (MEDI0382) is the most extensively developed dual GLP-1/glucagon receptor agonist, showing significant improvements in glucose control, BW (likely mediated by reduced energy intake rather than increased energy expenditure), hepatic fat, and albuminuria in a small RCT on patients with T2D and overweight or obesity 45,46
Despite its advantages, its important to acknowledge GHK-Cus limitations when compared to traditional acne treatments in a research context: Limited Direct Evidence for Active Acne Vulgaris: While it has anti-inflammatory properties, there is currently limited direct clinical evidence specifically demonstrating GHK-Cu as a primary treatment for active acne breakouts (e.g., reducing papules, pustules, or cysts)
J., Doll, M
Could Help with Chronic Pain Management DSIPs ability to promote restorative sleep is crucial, as poor sleep often amplifies the sensation of chronic pain
The goal is triggering the right cellular response, not flooding the system with excess peptide
It beats oral supplements hands down, delivering 100% absorption while pills only manage about 1.3% of a 1,000 mcg dose due to digestive hurdles
